Amsterdam, August 28: According to new research presented at the ESC Congress 2023, semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared to placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Feeling Safe From Crime Reduces Heart Attack Risk, Reveals Study.

Approximately half of patients with heart failure in the community have HFpEF. Most patients with HFpEF are overweight or obese, and growing evidence suggests that obesity and excess adiposity are not simply comorbidities, but may play a pivotal role in the development and progression of HFpEF.3 Patients with obesity-related HFpEF have an especially high burden of debilitating symptoms (shortness of breath, exertional intolerance, swelling/oedema) and physical limitations, which collectively result in a poor quality of life. Few treatment options are available, and there are no approved therapies specifically targeting the obesity phenotype of HFpEF.

Semaglutide is a potent glucagon-like-peptide-1 receptor agonist which has previously been shown to produce substantial weight loss in people with overweight and obesity. The STEP-HFpEF trial tested the hypothesis that treatment with semaglutide can significantly improve symptoms, physical limitations and exercise function, in addition to weight loss, in patients with HFpEF and obesity. Indian-Origin Scientists Identify 11 Risk Factors for Developing Dementia.

STEP-HFpEF was a randomised, double-blind, placebo-controlled trial conducted at 96 sites in 13 countries in Asia, Europe, North America and South America. The trial included patients with HFpEF (left ventricular ejection fraction ≥45 per cent), body mass index (BMI) ≥30 kg/m2, heart failure symptoms and functional limitations (New York Heart Association functional class II–IV and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score [KCCQ-CSS].

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)